PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML.
Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too.
Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Mais episódios de "OncoPharm"



Não percas um episódio de “OncoPharm” e subscrevê-lo na aplicação GetPodcast.








